Massimo Pinzani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Massimo Pinzani has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Vizzutti
Department of Experimental and Clinical Medicine University of Florence Florence Italy
9 shared publications - Fabio Marra
Department of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Florence, Florence, Italy
7 shared publications - Giacomo Laffi
Department of Experimental and Clinical Medicine, University of Florence, Italy
6 shared publications - Krista Rombouts
University College London (UCL), Institute for Liver & Digestive Health, London, UK
4 shared publications Umberto Arena
Dipartimento di Medicina Interna at the Università degli Studi di Firenze., F Vizzutti is a Gastroenterology Specialist and in charge of the Hepatic Hemodynamic Laboratory, and U Arena is a Gastroenterology Specialist and in charge of the Ultrasound Laboratory
4 shared publicationsLuigi Rega
Dipartimento di Fisiopatologia Clinica Sezione di Radiodiagnostica, Florence, Italy
3 shared publications
Latest Publications
- 1 October 2015
- Published by Elsevier in Journal of Hepatology
- Vol. 63 (4) , 778
Professor Paolo Gentilini, MD (1930–2015)
- 1 October 2015
- Published by Elsevier in Journal of Hepatology
- Vol. 63 (4) , 778
Professor Paolo Gentilini, MD (1930–2015)
- Open Access
- 1 December 2014
- Published by SciELO Agencia Nacional de Investigacion y Desarrollo (ANID) in Revista médica de Chile
- Vol. 142 (12) , 1553-1564
Efecto del ácido alfa lipoico y la pirfenidona en la modulación antioxidante celular contra el daño oxidativo
Liver fibrogenic processes are related to cellular redox state. Glutathione (GSH) is the major cellular antioxidant. GSH induced activation could be related to antifibrogenic effects.
- 1 December 2014
- Published by SciELO Agencia Nacional de Investigacion y Desarrollo (ANID) in Revista médica de Chile
- Vol. 142 (12) , 1553-1564
Open AccessEfecto del ácido alfa lipoico y la pirfenidona en la modulación antioxidante celular contra el daño oxidativo
Liver fibrogenic processes are related to cellular redox state. Glutathione (GSH) is the major cellular antioxidant. GSH induced activation could be related to antifibrogenic effects.
- Open Access
- 13 December 2011
- Published by Springer Nature in Fibrogenesis & Tissue Repair
- Vol. 4 (1) , 27
What is new in the liver sinusoids? meeting report, 16th International Symposium on Cells of the Hepatic Sinusoid (ISCHS)
The 16th International Symposium on Cells of the Hepatic Sinusoid (ISCHS) took place in Florence, Italy on 22-24 September 2011. This symposium is a multidisciplinary meeting where new and important findings on the biology of liver cells are presented and discussed.
- 13 December 2011
- Published by Springer Nature in Fibrogenesis & Tissue Repair
- Vol. 4 (1) , 27
Open AccessWhat is new in the liver sinusoids? meeting report, 16th International Symposium on Cells of the Hepatic Sinusoid (ISCHS)
The 16th International Symposium on Cells of the Hepatic Sinusoid (ISCHS) took place in Florence, Italy on 22-24 September 2011. This symposium is a multidisciplinary meeting where new and important findings on the biology of liver cells are presented and discussed.
- Open Access
- 1 August 2011
- Published by Elsevier in Journal of Hepatology
- Vol. 55 (2) , 459-465
Epithelial–mesenchymal transition in chronic liver disease: Fibrogenesis or escape from death?
- 1 August 2011
- Published by Elsevier in Journal of Hepatology
- Vol. 55 (2) , 459-465
Open AccessEpithelial–mesenchymal transition in chronic liver disease: Fibrogenesis or escape from death?
- 1 July 2011
- Published by S. Karger AG in Digestive Diseases
- Vol. 29 (2) , 243-248
Pathophysiology of Non-Alcoholic Steatohepatitis and Basis for Treatment
Non-alcoholic fatty liver disease (NAFLD) is likely the most common cause of liver disease in adults as well as in children and adolescents. Its occurrence is closely associated with obesity and insulin resistance. NAFLD may lead to non-alcoholic steatohepatitis (NASH) with possible evolution towards cirrhosis and hepatocellular carcinoma. In addition to steatosis, NASH is characterized by necroinflammation and fibrosis. While the presence of simple steatosis can be assessed by imaging studies, the occurrence of NASH and its staging requires a liver biopsy. Along these lines, major efforts are directed at identifying non-invasive methodologies able to discriminate simple NAFLD from NASH and to predict the stage of fibrotic evolution. Current treatment relies on weight loss and exercise, although various insulin-sensitizing agents, antioxidants and anti-inflammatory and antifibrogenic agents are under evaluation.
- 1 July 2011
- Published by S. Karger AG in Digestive Diseases
- Vol. 29 (2) , 243-248
Pathophysiology of Non-Alcoholic Steatohepatitis and Basis for Treatment
Non-alcoholic fatty liver disease (NAFLD) is likely the most common cause of liver disease in adults as well as in children and adolescents. Its occurrence is closely associated with obesity and insulin resistance. NAFLD may lead to non-alcoholic steatohepatitis (NASH) with possible evolution towards cirrhosis and hepatocellular carcinoma. In addition to steatosis, NASH is characterized by necroinflammation and fibrosis. While the presence of simple steatosis can be assessed by imaging studies, the occurrence of NASH and its staging requires a liver biopsy. Along these lines, major efforts are directed at identifying non-invasive methodologies able to discriminate simple NAFLD from NASH and to predict the stage of fibrotic evolution. Current treatment relies on weight loss and exercise, although various insulin-sensitizing agents, antioxidants and anti-inflammatory and antifibrogenic agents are under evaluation.
- 1 April 2011
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 25 (2) , 281-290
Liver cirrhosis
- 1 April 2011
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 25 (2) , 281-290
Liver cirrhosis
- 1 April 2011
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 25 (2) , 193-194
Foreword to liver fibrosis
- 1 April 2011
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 25 (2) , 193-194
Foreword to liver fibrosis
- 5 March 2011
- Published by Springer Nature
- p. 51-63
Stellate Cells and the Microcirculation
- 1 August 2010
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 4 (4) , 459-472
Update on the pathophysiology of liver fibrosis
Fibrogenesis represents the main pathophysiological consequence of chronic liver disease and leads to life-threatening clinical consequences. The knowledge in this field has grown exponentially in the past 20 years and, currently, evaluation and treatment of liver fibrosis are central issues in hepatology. Classic mechanisms of liver fibrogenesis have been expanded and consolidated over the past few years. Concomitantly, novel mechanisms have been suggested and demonstrated. The aim of this article is to provide an update on these mechanisms with an attempt to integrate classic and novel pathways responsible for the evolution of the fibrogenic process and, potentially, for its regression.
- 1 August 2010
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 4 (4) , 459-472
Update on the pathophysiology of liver fibrosis
Fibrogenesis represents the main pathophysiological consequence of chronic liver disease and leads to life-threatening clinical consequences. The knowledge in this field has grown exponentially in the past 20 years and, currently, evaluation and treatment of liver fibrosis are central issues in hepatology. Classic mechanisms of liver fibrogenesis have been expanded and consolidated over the past few years. Concomitantly, novel mechanisms have been suggested and demonstrated. The aim of this article is to provide an update on these mechanisms with an attempt to integrate classic and novel pathways responsible for the evolution of the fibrogenic process and, potentially, for its regression.